Novartis AG (NVS) vs BeOne Medicines AG (ONC)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NVS | ONC | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | MEGA | LARGE |
| Listing | NYSE | Nasdaq GS |
| Country | Switzerland | Switzerland |
| Theme | pharmaceuticals-large-cap | oncology |
| Price and returns | ||
| Last close | $153.81 | $370.87 |
| Return · 1 week | +2.40% | +0.19% |
| Return · 1 month | +4.72% | +1.05% |
| Return · 3 months | −3.78% | +12.23% |
| Return · year to date | +14.40% | +19.24% |
| Return · 1 year | +22.73% | +17.58% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −9.77% | −4.58% |
| 52-week high | $170.46 | $388.66 |
| 52-week low | $121.57 | $253.95 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $292.35B | $42.19B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $264.76M | $130.34M |
| Employees | 75,267 | 12,000 |
| Valuation | ||
| Price to earnings · trailing | 22.75× | 63.41× |
| Price to earnings · forward | 15.37× | 34.58× |
| Price to sales | 5.05× | 6.58× |
| Price to book | 6.89× | 7.74× |
| Enterprise value to EBITDA | 14.20× | 35.78× |
| Enterprise value to revenue | 5.79× | 6.26× |
| PEG ratio | 3.53 | 0.77 |
| Earnings per share · trailing | 6.62 | 5.59 |
| Profitability | ||
| Gross margin | 74.74% | 88.89% |
| Operating margin | 34.62% | 19.06% |
| Profit margin | 22.50% | 10.70% |
| Return on equity | 30.35% | 14.66% |
| Return on assets | 10.25% | 7.46% |
| Growth | ||
| Revenue growth | +0.80% | +29.60% |
| Earnings growth | −17.00% | +166.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | 116.85 | 39.61 |
| Current ratio | 0.86 | 3.41 |
| Dividend yield | 3.15% | 0.00% |
| Payout ratio | 71.60% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 61.14 | 53.70 |
| ADX · 14 | 18.61 | 12.72 |
| 50-day average | $148.17 | $363.07 |
| 200-day average | $151.49 | $324.35 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 1.93% | 3.04% |
The full NVS analysis
Everything this table leaves out for Novartis AG: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NVS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NVS analysisThe full ONC analysis
Everything this table leaves out for BeOne Medicines AG: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ONC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ONC analysis